Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A new microneedle system effectively delivers finasteride to treat hair loss.

This study successfully developed and optimized ethanol-free microemulsion systems for the transdermal delivery of finasteride, showing that the predicted optimal formulations had physicochemical characteristics close to estimated values, without significant damage to treated hair fibers.

This study found that transdermal delivery of finasteride using biomimetic Platycladi cacumen-derived nanovesicles enhanced hair regrowth in a mouse model of androgenetic alopecia, outperforming minoxidil by improving skin permeation, reducing oxidative stress, and boosting local drug retention.

This study found that coated microneedles promoted drug release effectively, comparable to marketed minoxidil solutions, with stable performance over 30 days at high temperatures.

In this study, researchers developed a novel gel formulation combining zinc oxide nanoparticles and finasteride-loaded nanostructured lipid carriers, which showed promising results for topical delivery and effective skin penetration, potentially offering a new treatment approach for androgenic alopecia.

This study found that niosomal aminexil was more clinically effective for hair growth than conventional aminexil solutions, and that niosomes facilitated aminexil penetration through rat skin without propylene glycol.

In this study, researchers developed topical tofacitinib-loaded cationic lipid nanoparticles, which improved absorption and targeted hair follicles in an ex vivo pig ear model, showing promise in treating alopecia areata by reducing symptoms through the JAK/STAT pathway.

This study developed a rapid and sensitive method for determining finasteride concentrations in pharmaceuticals, with results comparable to those from the standard HPLC method.

In this study, researchers employed a modified coaxial electrospinning technique to create core-sheath nanofibers, which improved the transdermal delivery of finasteride compared to traditional monolithic nanofibers, showing enhanced penetration rates throughout the testing period.

This study found that a specific amino-pyridine compound showed potent androgen receptor antagonist activity, stimulating hair growth in mice and reducing sebum production in a hamster model.

This study developed a personalized microneedle that delivers finasteride directly to the skin, facilitating a sustained release and potentially reducing side effects associated with oral administration.

This study developed a Neusilin® US2-based solid self-nanoemulsifying drug delivery system for finasteride that showed improved stability and drug delivery, with complete dissolution comparable to standard Propecia® tablets.

This study developed a stable lyophilized finasteride nanosystem for topical delivery and found that it was stable for 90 days and that formulations with 15% trehalose showed favorable characteristics for potential use in treating androgenic alopecia.

This study found that the newly developed microarray patches for intradermal delivery of finasteride showed high drug content and significantly improved skin deposition compared to existing methods.

This study developed a peptide-based topical delivery system that enhanced hair growth with reduced systemic exposure to finasteride, showing efficacy comparable to 5% minoxidil in vivo while using significantly less finasteride than oral doses.

This study reported that a new formulation of finasteride solid lipid nanoparticles, combined with LPC and NTC, enhanced hair growth in mice without visible skin reactions, suggesting it could effectively manage androgenetic alopecia.

This study found that in a mouse model of androgenetic alopecia, topical application of finasteride-loaded Platycladi cacumen-derived nanovesicles improved hair regrowth more effectively than minoxidil.

This study found that polymeric nanoparticles may effectively deliver finasteride topically to hair follicles, potentially improving alopecia treatment with fewer side effects than oral forms.

This study suggests that novel lipid nanoparticle formulations may be suitable for delivering anti-alopecia compounds like minoxidil and finasteride, although their skin penetration was limited.